About Aduro Biotech (NASDAQ:ADRO)
Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The Company's product candidates from its Live, Attenuated, Double-Deleted (LADD) Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. Its LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers. Its LADD product candidate is CRS-207, which is being developed as a treatment for multiple indications, including mesothelioma, ovarian and gastric cancers. ADU-214 and ADU-741 are product candidates in development for lung and prostate cancers, respectively.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:ADRO
- CUSIP: N/A
- Web: www.aduro.com
- Market Cap: $686.43 million
- Outstanding Shares: 74,612,000
- 50 Day Moving Avg: $10.68
- 200 Day Moving Avg: $10.87
- 52 Week Range: $8.75 - $15.52
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -7.30
- P/E Growth: 0.06
- Annual Revenue: $17.36 million
- Price / Sales: 39.54
- Book Value: $3.50 per share
- Price / Book: 2.63
- EBITDA: ($94,740,000.00)
- Net Margins: -609.58%
- Return on Equity: -43.92%
- Return on Assets: -23.46%
- Current Ratio: 13.33%
- Quick Ratio: 13.33%
- Average Volume: 402,740 shs.
- Beta: 3.58
- Short Ratio: 17.19
Frequently Asked Questions for Aduro Biotech (NASDAQ:ADRO)
What is Aduro Biotech's stock symbol?
Aduro Biotech trades on the NASDAQ under the ticker symbol "ADRO."
How were Aduro Biotech's earnings last quarter?
Aduro Biotech, Inc. (NASDAQ:ADRO) announced its quarterly earnings data on Thursday, August, 3rd. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.25) by $0.02. The company had revenue of $5.90 million for the quarter, compared to analyst estimates of $3.98 million. Aduro Biotech had a negative return on equity of 43.92% and a negative net margin of 609.58%. The firm's revenue for the quarter was down 84.9% on a year-over-year basis. During the same period last year, the firm earned $0.03 earnings per share. View Aduro Biotech's Earnings History.
Where is Aduro Biotech's stock going? Where will Aduro Biotech's stock price be in 2017?
8 brokers have issued twelve-month target prices for Aduro Biotech's stock. Their predictions range from $14.00 to $30.00. On average, they anticipate Aduro Biotech's share price to reach $20.00 in the next year. View Analyst Ratings for Aduro Biotech.
What are analysts saying about Aduro Biotech stock?
Here are some recent quotes from research analysts about Aduro Biotech stock:
- 1. According to Zacks Investment Research, "Aduro’s lead candidate, CRS-207, being evaluated for a number of cancer indications, bodes well for long-term growth. Moreover, its collaboration agreements with large pharma companies, Novartis, Johnson & Johnson and Incyte are big positives for the company. Aduro has a broad and a promising pipeline of novel immunotherapies under development for the treatment of a variety of cancers. Aduro’s efforts to develop its pipeline are encouraging. However, Aduro depends largely on funds generated from collaboration and license agreements, government grants and other payments for the development of its pipeline candidates. Thus, inability to secure sufficient funding could hinder its pipeline progress. Aduro’s shares underperformed the industry in the last one year. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has mixed record of earnings surprises in recent quarters." (8/2/2017)
- 2. Canaccord Genuity analysts commented, "1Q17 results recap. Adjusted non-GAAP revenue (excluding the individual commercial business) grew 4.4% year over year. Adjusted MLR was 85.2% compared to 85.0% a year ago. MLR benefitted from the exit of certain Medicare markets, which was offset to some degree by lower prior period development when compared to a year ago. Cost trends appear to be in check, consistent with other publicly-traded health insurers." (5/3/2017)
- 3. FBR & Co analysts commented, "Aduro Biotech, Inc.’s (ADRO) cancer immunotherapy platform triggers both innate and adaptive immunity, resulting in a broad and potent multi-pronged immune response. The company’s engineered live, attenuated, double-deleted (LADD) Listeria monocytogenes program is capable of inducing an antigen-specific adaptive T-cell response (CD8+ and CD4+), as well as an innate immune response that includes cytokines, chemokines, gamma delta T cells, and NK cells. The company’s STING (Stimulator of Interferon Genes, driven by cytosolic DNA) platform induces dendritic cells and enhances an anti-tumor T-cell response in the tumor microenvironment. Aduro’s third technology platform is B-select, based on clonal expansion of B cells producing highly selective and functional antibodies against targets that regulate the immune response. Given that the future of cancer immunotherapy points to combinations, Aduro’s programs are complementary combination approaches that activate distinct mechanisms of actions that could be synergistic." (3/7/2017)
Who are some of Aduro Biotech's key competitors?
Some companies that are related to Aduro Biotech include Five Prime Therapeutics (FPRX), MyoKardia (MYOK), Clinigen Group PLC (CLIN), Ascendis Pharma A/S (ASND), Acorda Therapeutics (ACOR), Dermira (DERM), Lexicon Pharmaceuticals (LXRX), Epizyme (EPZM), Sangamo Therapeutics (SGMO), Dynavax Technologies Corporation (DVAX), NeuroDerm (NDRM), REGENXBIO (RGNX), Xencor (XNCR), Athenex (ATNX), Retrophin (RTRX), Amarin Corporation PLC (AMRN), Ignyta (RXDX) and Reata Pharmaceuticals (RETA).
Who are Aduro Biotech's key executives?
Aduro Biotech's management team includes the folowing people:
- Stephen T. Isaacs, Chairman of the Board, President and Chief Executive Officer
- Gregory W. Schafer, Chief Operating Officer
- Blaine Templeman, Executive Vice President, General Counsel, Secretary
- Dirk G. Brockstedt, Executive Vice President of Research and Development
- Jennifer Lew CPA, Senior Vice President - Finance
- Andrea van Elsas Ph.D., Chief Scientific Officer
- Natalie R. Sacks, Chief Medical Officer
- Stephanie Monaghan O'Brien J.D., Lead Independent Director
- Gerald Chan Ph.D., Independent Director
- William M. Greenman, Independent Director
When did Aduro Biotech IPO?
(ADRO) raised $119 million in an initial public offering on Wednesday, April 15th 2015. The company issued 7,000,000 shares at $17.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
Who owns Aduro Biotech stock?
Aduro Biotech's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include
MORNINGSIDE VENTURE (VI) INVESTMENTS LTD
(12.47%). Company insiders that own Aduro Biotech stock include Blaine Templeman, Dirk G Brockstedt, Elsas Andrea Van, Gregory W Schafer, Jennifer Lew, Ross Haghighat, Stephen T Isaacs and Thomas W Dubensky. View Institutional Ownership Trends for Aduro Biotech.
How do I buy Aduro Biotech stock?
Shares of Aduro Biotech can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Aduro Biotech's stock price today?
MarketBeat Community Rating for Aduro Biotech (NASDAQ ADRO)MarketBeat's community ratings are surveys of what our community members think about Aduro Biotech and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Aduro Biotech stock can currently be purchased for approximately $9.20.
Consensus Ratings for Aduro Biotech (NASDAQ:ADRO) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||8 Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$20.00 (117.39% upside)|Consensus Price Target History for Aduro Biotech (NASDAQ:ADRO)
Analysts' Ratings History for Aduro Biotech (NASDAQ:ADRO)
(Data available from 10/22/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/17/2017||HC Wainwright||Set Price Target||Buy||$18.00||N/A|
|10/2/2017||William Blair||Reiterated Rating||Outperform||High|
|8/3/2017||Canaccord Genuity||Set Price Target||Buy||$30.00||Low|
|7/18/2017||Cowen and Company||Initiated Coverage||Outperform||Low|
|5/1/2017||Rodman & Renshaw||Initiated Coverage||Buy -> Buy||$18.00||Low|
|3/7/2017||FBR & Co||Reiterated Rating||Buy||$23.00||N/A|
|3/7/2017||Roth Capital||Reiterated Rating||Buy||$17.00||N/A|
|10/24/2016||Leerink Swann||Set Price Target||Buy||$14.00||N/A|
|3/15/2016||Bank of America Corporation||Downgrade||Buy -> Underperform||$32.00 -> $14.00||N/A|
|12/1/2015||Oppenheimer Holdings, Inc.||Downgrade||Outperform -> Market Perform||N/A|
Earnings History for Aduro Biotech (NASDAQ:ADRO)Earnings History by Quarter for Aduro Biotech (NASDAQ ADRO)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|8/3/2017||Q2 2017||($0.25)||($0.27)||$3.98 million||$5.90 million||View||N/A|
|5/2/2017||Q1 2017||($0.39)||($0.32)||$3.74 million||$3.77 million||View||N/A|
|3/1/2017||Q4 2016||($0.40)||($0.44)||$3.83 million||$3.88 million||View||N/A|
|11/2/2016||Q3 2016||($0.45)||($0.54)||$3.99 million||$3.79 million||View||N/A|
|8/3/2016||Q2 2016||($0.18)||$0.03||$25.24 million||$39.00 million||View||N/A|
|5/2/2016||Q116||($0.25)||($0.45)||$13.47 million||$4.03 million||View||N/A|
|3/8/2016||Q415||($0.15)||$0.04||$17.55 million||$34.38 million||View||N/A|
|11/23/2015||Q3||($0.08)||$0.01||$15.80 million||$19.15 million||View||N/A|
|8/10/2015||Q215||($0.01)||($0.18)||$1.00 million||$9.90 million||View||N/A|
|5/28/2015||Q115||($0.08)||($39.97)||$12.03 million||$9.60 million||View||N/A|
Earnings Estimates for Aduro Biotech (NASDAQ:ADRO)
2017 EPS Consensus Estimate: ($1.52)
2018 EPS Consensus Estimate: ($1.26)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Aduro Biotech (NASDAQ:ADRO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Aduro Biotech (NASDAQ:ADRO)
Insider Ownership Percentage: 6.60%Insider Trades by Quarter for Aduro Biotech (NASDAQ:ADRO)
Institutional Ownership Percentage: 35.05%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|10/2/2017||Dirk G Brockstedt||EVP||Sell||10,000||$10.59||$105,900.00|| |
|10/2/2017||Gregory W Schafer||COO||Sell||20,000||$10.75||$215,000.00|| |
|10/2/2017||Jennifer Lew||Insider||Sell||6,600||$10.61||$70,026.00|| |
|10/2/2017||Stephen T Isaacs||CEO||Sell||40,000||$10.78||$431,200.00|| |
|9/18/2017||Blaine Templeman||VP||Sell||2,884||$11.20||$32,300.80|| |
|9/13/2017||Blaine Templeman||VP||Sell||3,557||$10.99||$39,091.43|| |
|9/13/2017||Elsas Andrea Van||Insider||Sell||4,922||$10.99||$54,092.78|| |
|9/13/2017||Gregory W Schafer||COO||Sell||4,859||$10.99||$53,400.41|| |
|9/1/2017||Dirk G Brockstedt||EVP||Sell||10,000||$11.69||$116,900.00|| |
|9/1/2017||Gregory W Schafer||COO||Sell||20,000||$11.70||$234,000.00|| |
|9/1/2017||Jennifer Lew||Insider||Sell||6,600||$11.70||$77,220.00|| |
|8/11/2017||Thomas W Dubensky||Insider||Sell||50,000||$11.38||$569,000.00|| |
|8/10/2017||Thomas W Dubensky||Insider||Sell||40,912||$11.43||$467,624.16|| |
|8/8/2017||Gregory W Schafer||COO||Sell||40,000||$12.17||$486,800.00|| |
|8/7/2017||Dirk G Brockstedt||EVP||Sell||10,000||$12.18||$121,800.00|| |
|8/7/2017||Gregory W Schafer||COO||Sell||25,811||$12.17||$314,119.87|| |
|8/7/2017||Jennifer Lew||Insider||Sell||6,600||$12.17||$80,322.00|| |
|8/7/2017||Stephen T Isaacs||CEO||Sell||40,000||$12.19||$487,600.00|| |
|7/6/2017||Thomas W Dubensky||Insider||Sell||50,000||$11.33||$566,500.00|| |
|7/5/2017||Stephen T Isaacs||Insider||Sell||40,000||$11.06||$442,400.00|| |
|7/3/2017||Dirk G Brockstedt||EVP||Sell||10,000||$11.02||$110,200.00|| |
|7/3/2017||Jennifer Lew||Insider||Sell||12,000||$11.14||$133,680.00|| |
|6/28/2017||Gregory W Schafer||COO||Sell||40,000||$11.26||$450,400.00|| |
|6/28/2017||Jennifer Lew||Insider||Sell||12,000||$11.19||$134,280.00|| |
|6/19/2017||Stephen T Isaacs||Insider||Sell||40,000||$10.50||$420,000.00|| |
|6/5/2017||Thomas W Dubensky||Insider||Sell||144,301||$10.03||$1,447,339.03|| |
|5/17/2017||Blaine Templeman||VP||Sell||1,648||$9.65||$15,903.20|| |
|5/17/2017||Dirk G. Brockstedt||EVP||Sell||1,011||$9.65||$9,756.15|| |
|5/16/2017||Stephen T. Isaacs||CEO||Sell||16,673||$10.00||$166,730.00|| |
|5/16/2017||Stephen T. Isaacs||insider||Sell||27,273||$10.01||$273,002.73|| |
|5/15/2017||Stephen T. Isaacs||CEO||Sell||10,600||$10.01||$106,106.00|| |
|5/12/2017||Thomas W Dubensky||Insider||Sell||5,699||$9.92||$56,534.08|| |
|5/11/2017||Dirk G Brockstedt||EVP||Sell||8,000||$9.72||$77,760.00|| |
|4/3/2017||Dirk G Brockstedt||EVP||Sell||8,000||$10.71||$85,680.00|| |
|4/3/2017||Stephen T Isaacs||Insider||Sell||27,273||$10.28||$280,366.44|| |
|3/13/2017||Stephen T Isaacs||Insider||Sell||27,273||$11.35||$309,548.55|| |
|3/9/2017||Dirk G Brockstedt||EVP||Sell||8,000||$11.00||$88,000.00|| |
|3/9/2017||Thomas W Dubensky||Insider||Sell||25,000||$10.96||$274,000.00|| |
|1/17/2017||Dirk G Brockstedt||EVP||Sell||8,000||$11.86||$94,880.00|| |
|1/11/2017||Blaine Templeman||VP||Sell||3,785||$11.95||$45,230.75|| |
|1/3/2017||Stephen T Isaacs||Insider||Sell||27,273||$11.12||$303,275.76|| |
|12/1/2016||Thomas W Dubensky||Insider||Sell||25,000||$10.94||$273,500.00|| |
|11/14/2016||Ross Haghighat||Director||Sell||7,088||$15.50||$109,864.00|| |
|10/3/2016||Stephen T Isaacs||CEO||Sell||27,273||$12.67||$345,548.91|| |
|10/3/2016||Thomas W Dubensky||Insider||Sell||25,000||$12.68||$317,000.00|| |
|9/19/2016||Jennifer Lew||Insider||Sell||6,360||$14.95||$95,082.00|| |
|9/1/2016||Thomas W Dubensky||Insider||Sell||25,000||$14.03||$350,750.00|| |
|8/11/2016||Thomas W Dubensky||Insider||Sell||25,000||$15.18||$379,500.00|| |
|7/5/2016||Thomas W Dubensky||Insider||Sell||25,000||$11.61||$290,250.00|| |
|5/16/2016||Thomas W. Dubensky||Insider||Sell||905||$8.20||$7,421.00|| |
|1/11/2016||Dirk G. Brockstedt||VP||Sell||22,000||$21.77||$478,940.00|| |
|1/8/2016||Gregory W. Schafer||COO||Sell||20,000||$23.58||$471,600.00|| |
|1/6/2016||Jennifer Lew||VP||Sell||5,242||$25.71||$134,771.82|| |
|1/5/2016||Stephen T. Isaacs||CEO||Sell||25,000||$26.31||$657,750.00|| |
|1/4/2016||Thomas W. Dubensky||insider||Sell||15,000||$26.37||$395,550.00|| |
|12/7/2015||Gregory W. Schafer||COO||Sell||25,000||$29.74||$743,500.00|| |
|12/3/2015||Jennifer Lew||VP||Sell||5,242||$29.85||$156,473.70|| |
|12/1/2015||Stephen T. Isaacs||CEO||Sell||25,000||$29.11||$727,750.00|| |
|12/1/2015||Thomas W. Dubensky||insider||Sell||30,000||$29.27||$878,100.00|| |
|11/18/2015||Jennifer Lew||VP||Sell||6,712||$28.52||$191,426.24|| |
|11/17/2015||Gregory W. Schafer||COO||Sell||26,470||$28.15||$745,130.50|| |
|11/17/2015||Thomas W. Dubensky||insider||Sell||31,470||$28.27||$889,656.90|| |
|11/16/2015||Stephen T. Isaacs||CEO||Sell||25,000||$27.54||$688,500.00|| |
|4/20/2015||Jennifer Lew||VP||Buy||2,000||$17.00||$34,000.00|| |
|4/20/2015||Venture (Vi) Inves Morningside||Major Shareholder||Buy||441,176||$17.00||$7,499,992.00|| |
|4/20/2015||William Mariner Greenman||Director||Buy||3,000||$17.00||$51,000.00|| |
Headline Trends for Aduro Biotech (NASDAQ:ADRO)
Latest Headlines for Aduro Biotech (NASDAQ:ADRO)
Loading headlines, please wait.
Aduro Biotech (ADRO) Chart for Sunday, October, 22, 2017